First Tracks Biotherapeutics (TRAX) Corporate presentation summary

Portfolio and funding

• Focused immunology pipeline spans ANB033, a CD122 antagonist; rosnilimab, a pathogenic T-cell depleter; and ANB101, a BDCA2 modulator.

• ANB033 is in Phase 1b trials for celiac disease and eosinophilic esophagitis; Phase 2 expansion into vitiligo and one additional indication is anticipated in H1 2027.

• Pro forma cash of $343 million includes $155.6 million in cash, equivalents and investments at Sept. 30, 2026, plus $200 million net proceeds from an Oct. 15 private placement.

ANB033 in celiac disease

• In Phase 1b Cohort 1, ANB033 reduced gluten-challenge-related Vh:Cd decline versus placebo by 0.49 (p=0.009); the ANB033 change was -0.17 versus -0.66 for placebo.

• IEL density change favored ANB033 by 20.03 (p<0.001), and the VCIEL composite treatment difference was 3.33 (p=0.002).

• ANB033 prevented a rise in symptoms during the gluten challenge; symptom scores favored treatment, with statistically significant differences reported from Day 1.

• The Cohort 1 efficacy analysis included 32 participants; treatment was well tolerated, with no safety signals reported in the study analysis.

• Cohort 2 assesses mucosal healing in participants with existing histologic activity; top-line data are anticipated in Q1 2027, with a late-stage trial planned for 2027.

ANB033 in eosinophilic esophagitis

• ANB033 targets CD122 signaling through IL-2 and IL-15 pathways; the presentation describes potential to address both dupilumab-sensitive and -insensitive inflammatory drivers.

• Phase 1b is ongoing in EoE, with 50 participants randomized 1:1 to ANB033 or placebo for 12 weeks; top-line data are anticipated in Q3 2027.

• Preclinical models showed reduced eosinophilic inflammation and lower IL-5, IL-13 and eotaxin secretion following ANB033 treatment.

• The presentation estimates a U.S. EoE opportunity exceeding $15 billion, with ~200,000 biologic-eligible adult patients.